Company Overview and News

Arafura awards Hatch engineering contract

Arafura Resources has appointed engineering consultancy, Hatch, as the lead engineering study manager for the definitive feasibility study at the Nolans neodymium-praseodymium (NdPr) project in the Northern Territory.

Central Australia onshore gas exploration increases, while minerals slowly recover

Santos previously owned the Mereenie oil and gas field west of Alice Springs, before selling to Macquarie Group.

Arafura’s rare earth Nolan project in NT receives environmental approval

Arafura Resources last week received environmental approvals from the Northern Territory EPA’s (Environment Protection Authority) environmental impact assessment report for its Nolans rare earths project. The project, which is 135km north of Alice Springs, is focused on the development of neodymium and praseodymium.

Arafura Resources makes steady progress at Nolans rare earth project

Arafura Resources (ASX:ARU) has successfully completed bulk pre-leach piloting for its Nolans Neodymium-Praseodymium (NdPr) Project in the Northern Territory.

Why the next mining boom will be driven by tech metals

There are rare earth deposits across the world, but they are difficult to find in economic quantities.

Why the next mining boom will be driven by tech metals

The Australian mining industry is on the verge of a new mining boom based around so-called tech metals.

Global Rare Earth Metals Market 2017-2021

2017-04-12 prnewswire
LONDON, April 12, 2017 /PRNewswire/ -- About Rare Earth Metals Rare earth metals comprise 17 chemical elements in the periodic table, which include fifteen elements of the lanthanide series, and scandium and yttrium. Scandium and yttrium are also considered rare earth metals as they are found in the same mineral ore deposits as the other elements of the lanthanide series. Rare earth metals have unique physical and chemical properties, which make them suitable to alloy with other metals in applications that require properties such as enhanced magnetic strength and high-temperature resistance.

Arafura Resources secures funds to progress Nolans project

Arafura Resources (ASX:ARU) has raised $3,133,500 from shareholders via a share purchase plan at $0.060 per share.

Arafura Resources advancing to the next phase at Nolans Project

Arafura Resources (ASX:ARU) is progressing to the next phase of piloting at its Nolans Neodymium-Praseodymium Project in the Northern Territory.

Force Commodities welcomes leadership change ahead of detail project overview

Force Commodities (ASX:4CE) has appointed new board and management for the progression of commercialisation studies for the company’s assets.

Arafura taps investors for $5m

Rare earths explorer Arafura Resources has announced a $5.1 million capital raising to fund ongoing work at its Nolans project in the Northern Territory.

Arafura Resources to lift cash position on back of stronger share price

Arafura Resources (ASX:ARU) shares last traded at $0.10, or close to double their value from the beginning of 2017, as investors provide support for the company's wholly-owned Nolans Neodymium-Praseodymium Project in the Northern Territory.

Arafura Resources gets cash boost for neodymium project

The receipt of these funds brings the total cash receipts from the government’s rebate incentive to $35.2 million. Arafura’s current cash reserves stands at $9.8 million.

Arafura Resources completes beneficiation pilot at Nolans

The beneficiation pilot plant is the first stage of Arafura’s final piloting of the Nolans process flow sheet. The beneficiation piloting operation was completed during November-December at ALS Global’s facilities in Perth. Arafura managed the program under advice from equipment manufacturers and independent engineering organisations. The pilot plant’s success, including materials handling and equipment performance data, will be utilised for detailed design and final feasibility.

Arafura Resources Ltd awarded major project status for Nolans

Arafura Resources Ltd (ASX:ARU) has attained Major Project Facilitation (MPF) status with the Australian Government for its Nolans Rare Earths Project in the Northern Territory. The MPF status will provide Nolans with tailored facilitation services to support a timely and efficient approval process. This will include the coordination of all relevant Australian and Northern Territory government processes so that they occur, as far as practicable, simultaneously and without delay.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

20h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

20h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...